Pramodini Medicare Ltd IPO
- Price band
- ₹110 to ₹118
- Issue size
- ₹69.04 Cr
- Issue price
- ₹118
- Lot size
- 1,200 shares
- Min. investment
- ₹2,83,200
- Listing return
- +1.69%
2,400 shares
Listed ₹120
Opens
12 Aug 2026
Closes
14 Aug 2026
Allotment
17 Aug 2026
Listing
19 Aug 2026
Subscription
About the company
Pramodini Medicare Ltd is an Indian diagnostic services company that uses technology to serve public and private hospitals, government PSUs and medical colleges in tier I, tier II and tier III cities. Its offering spans three areas: radiology (MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, Dexa scans and interventional radiology), clinical laboratory work (haematology, microbiology, immunology, pathology and biochemistry) and nuclear medicine (PET-CT, SPECT and nuclear therapy).
A 24×7 teleradiology operation runs from the registered office in Vijayawada, where the company also has a processing unit-cum-laboratory. As of December 31, 2025, it ran 15 diagnostic centres spread over six states and 13 cities, delivered through public-private partnerships, private-private partnerships, tie-ups with government PSUs and standalone private centres.
Objective of IPO proceeds
| Particulars | Estimated amount (₹ Cr.) |
|---|---|
| Funding of capital expenditure for purchase of medical equipments towards existing and proposed diagnostic centres | 45.15 |
| General corporate purposes | — |
Key performance indicators (KPIs)
for the year ended March 31, 2026
- ROE39.08%
- ROCE34.66%
- EBITDA Margin49.61%
- PAT Margin27.9%
- Return on Net Worth (RoNW)32.69%
Debt/Equity Ratio
0.34
Net Asset Value (NAV) per Equity Share
31.84
EPS (Pre-IPO)
10.41
View table
| KPI | Value (for the year ended March 31, 2026) |
|---|---|
| ROE (%) | 39.08 |
| ROCE (%) | 34.66 |
| EBITDA Margin (%) | 49.61 |
| Debt/Equity Ratio | 0.34 |
| PAT Margin (%) | 27.9 |
| Return on Net Worth (RoNW) (%) | 32.69 |
| Net Asset Value (NAV) per Equity Share (₹) | 31.84 |
| EPS (Pre-IPO) (₹) | 10.41 |
Financials
₹ croreRevenue
38.24
Total Assets
53.27
Profit
11.54
View table
| Line | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 30.58 | 35.23 | 38.24 |
| Total Assets | 47.47 | 46.59 | 53.27 |
| Profit | 5.87 | 7.62 | 11.54 |
Book running lead managers & registrar
| Book running lead managers | Smart Horizon Capital Advisors Private Limited |
|---|---|
| Registrar to the issue | Purva Sharegistry (India) Private Limited |
Pramodini Medicare IPO contact details
| Company name | Pramodini Medicare Limited |
|---|---|
| Registered office | D.No: - 29-4-54K, CSI Complex, Prakasam Road, Suryaraopet, Vijayawada, Andhra Pradesh, India – 520002 |
| Phone | +91 9985782727 |
| investors@pramodinidiagnostics.com | |
| Website | www.pramodinidiagnostics.com |
Pramodini Medicare IPO registrar contact details
| Company name | Purva Sharegistry (India) Private Limited |
|---|---|
| Phone | 022 - 49614132 |
| newissue@purvashare.com | |
| Website | www.purvashare.com |
Thesis
- 1
The network reached 15 diagnostic centres in 13 cities across six states as of December 31, 2025, covering Uttar Pradesh, Andhra Pradesh, Karnataka, West Bengal, Haryana/NCR Delhi and Kerala, though the Kerala operations were yet to start.
- 2
Services are delivered under four models: seven public-private partnership centres, three private-private partnerships, three strategic tie-ups with government PSUs and two standalone private centres, plus a processing unit.
- 3
The equipment fleet as of December 31, 2025 included seven CT and seven MRI machines, 20 X-ray units, 15 ultrasound machines, two Dexa and two mammography machines, one PET-CT, six CR systems and three DR systems.
- 4
Revenue comes from B2G, B2B and B2C segments; in the nine months to December 31, 2025, government business was 61.32% of revenue from operations, B2B 20.09% and B2C 18.60%.
- 5
Radiology and pathology both run on technology-enabled platforms, with MRI, CT, X-ray, ultrasound, Dexa and mammography on the imaging side and fully automatic analysers for routine and specialised pathology tests.
- 6
Both revenue from operations and PAT have grown steadily: revenue rose from Rs 30.58 crore in FY23 to Rs 35.23 crore in FY24 and Rs 38.24 crore in FY25, while PAT climbed from Rs 5.87 crore to Rs 7.62 crore and then Rs 11.54 crore over the same years.
Application details
Individual investor
₹110 - ₹118 · from ₹2,00,000 onwards.
1,200sharesMin 2,400
Figures come from the company filing. This is not a recommendation.